• Trump's executive order targets up to 59% reduction in U.S. drug prices by tying Medicare costs to international benchmarks.
  • The revived 'Most Favored Nation' policy faces likely legal challenges from pharmaceutical companies, mirroring its 2020 blockage.
  • While focused on prescriptions, Trump's Truth Social post suggested unspecified plans to lower gasoline, energy, and grocery costs.

Reviving the Drug Pricing Battle

Former President Donald Trump has announced plans to sign an executive order implementing a 'Most Favored Nation' (MFN) policy for prescription drugs, claiming it could slash U.S. prices by 59% or more. The measure would force Medicare to pay no more than the lowest prices negotiated by other developed nations—a revival of his 2020 effort that was struck down by federal courts after pharmaceutical industry lawsuits.

'We're going to get the best prices anywhere in the world,' Trump said in a Truth Social post that also vaguely promised reductions in 'gasoline, energy, groceries, and all other costs.' No specific policies for those sectors were detailed, leaving analysts questioning whether the remarks signaled forthcoming proposals or rhetorical flourish.

The MFN Mechanics

The policy specifically targets Medicare Part B and D drugs, with HHS directed to implement international reference pricing. Early estimates suggest potential discounts up to 60% for certain cancer treatments, alongside expanded low-cost insulin and epinephrine access for uninsured patients—building on Trump's 2020 initiative that achieved 22% savings before being halted.

Pharmaceutical Research and Manufacturers of America (PhRMA), which successfully blocked the prior attempt, is expected to mount immediate legal challenges. 'Price controls stifle innovation and limit patient access,' a PhRMA spokesperson said in a statement last year regarding similar proposals.

Uncharted Legal and Market Terrain

While the order's drug pricing mechanism has precedent in other countries, its U.S. viability remains uncertain. Courts previously ruled the 2020 version exceeded executive authority without Congressional action. However, Trump's team insists new legal strategies will overcome these hurdles, with one advisor noting 'lessons learned' from prior litigation.

Market reaction was muted pending concrete action, though healthcare stocks dipped slightly on the news. The broader implications—including how savings might affect pharmaceutical R&D budgets—remain hotly debated among analysts. As the Biden administration concurrently pursues Medicare price negotiations, the stage is set for a contentious election-year showdown over one of voters' top economic concerns.